CGT9486
Phase 3Small molecule
CGT9486 is one of 53 small molecule programs targeting Gastrointestinal Stromal Tumor. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
85 competitors in Gastrointestinal Stromal Tumor
#DrugCompanyPhaseTrials
1Stivarga
BayerPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Luye
Ascentage Pharma Group Inc.Phase 3
Votrient
NovartisPhase 2
TKI258
NovartisPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Tecentriq
RochePhase 2
Lenvima
EisaiPhase 2
Taxol
TevaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CGT9486. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCogent Biosciences, Inc.